New eczema drug ARQ-234 enters first human trials
NCT ID NCT07453602
First seen Mar 15, 2026 · Last updated May 12, 2026 · Updated 5 times
Summary
This early-stage study tests a new drug called ARQ-234 for people with moderate to severe atopic dermatitis (eczema). The main goal is to check if the drug is safe and how the body processes it. The study includes healthy volunteers and people with eczema, who will receive either the drug or a placebo. It is not yet known if ARQ-234 will effectively treat eczema symptoms.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ATOPIC DERMATITIS (AD) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Clinical Site 101
RECRUITINGFair Lawn, New Jersey, 07410, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.